Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

F. Apperley, Jane; Gardembas, Martine; V. Melo, Junia; Russell‐Jones, R.; J. Bain, Barbara; Joanna Baxter, E.; Chase, Andrew; M. Chessells, Judith; Colombat, Marie; Dearden, Claire; Dimitrijević, Saša; Mahon, François-X.; Marin, David; Nikolova, Zariana; Olavarría, Eduardo; Silberman, Sandra; Schultheis, Beate; C.P. Cross, Nicholas; M. Goldman, John

doi:10.1056/nejmoa020150

Public

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Published in New England Journal of Medicine • Aug 15, 2002

Authors:

Jane F. Apperley

Martine Gardembas

Junia V. Melo

Abstract

BACKGROUND: A small proportion of patients with chronic myeloproliferative diseases have constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), which encodes a receptor tyrosine kinase. The gene is located on chromosome 5q33, and the activation is usually caus...

Subject

PDGFRB

Imatinib mesylate

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!